Long-term management of canine disseminated granulomatous meningoencephalitis with imatinib mesylate: a case report

https://doi.org/10.17221/70/2018-VETMEDCitation:Song J., Hwang T., Lee H., Yu D., Seung B., Sur J., Jung D. (2019): Long-term management of canine disseminated granulomatous meningoencephalitis with imatinib mesylate: a case report. Veterinarni Medicina, 64: 92-99.
download PDF

A seven-year-old Toy Poodle was presented for progressive ataxia and seizure episodes. Magnetic resonance imaging revealed inflammatory lesions in the cerebrum and brainstem. Management with imatinib mesylate, prednisolone and hydroxyurea were initiated and resulted in complete resolution of the clinical signs. In regular magnetic resonance imaging scans, the overall appearance of the lesions deteriorated but improved again after an increase in the imatinib mesylate dose. The patient had not shown any neurological signs until death and survived for 1052 days after initial presentation. On histopathological examination, the patient was diagnosed with disseminated granulomatous meningoencephalitis involving the cerebrum and brainstem. Immunohistochemical staining was performed on the five types of tyrosine kinase (PDGFR-α, PDGFR-ß, VEGFR-2, c-Kit and c-Abl proteins), which constitute therapeutic targets for conventional multitargeted tyrosine kinase inhibitors. The immunohistochemical analysis revealed that all these tyrosine kinases were expressed in the brain samples. The present report describes the first case of the use of imatinib mesylate therapy for granulomatous meningoencephalitis in the dog. Therapy with imatinib mesylate plus glucocorticoids appears promising as a new therapeutic intervention in meningoencephalitis of unknown aetiology.

References:
Akashi Naotsugu, Matsumoto Isao, Tanaka Yoko, Inoue Asuka, Yamamoto Kayo, Umeda Naoto, Tanaka Yuki, Hayashi Taichi, Goto Daisuke, Ito Satoshi, Sekiguchi Kaneo, Sumida Takayuki (2014): Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis. Modern Rheumatology, 21, 267-275 https://doi.org/10.3109/s10165-010-0392-5
 
Azizi G, Mirshafiey A (2013): Imatinib mesylate: An innovation in treatment of autoimmune diseases. Recent Patents on Inflammation & Allergy Drug Discovery 7, 259–267.
 
Azizi G, Haidari MR, Khorramizadeh M, Naddafi F, Sadria R, Javanbakht MH, Sedaghat R, Zavareh FT, Mirshafiey A (2014): Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants. Iranian Journal of Allergy, Asthma and Immunology 13, 198–206.
 
Bonkobara Makoto (2015): Dysregulation of tyrosine kinases and use of imatinib in small animal practice. The Veterinary Journal, 205, 180-188 https://doi.org/10.1016/j.tvjl.2014.12.015
 
Braund K (1985): Granulomatous meningoencephalomyelitis. Journal of the American Veterinary Medical Association 186, 138–141.
 
Coates Joan R. (2007): Emerging treatments for granulomatous meningoencephalomyelitis (GME). Advances in Small Animal Medicine and Surgery, 20, 1-3 https://doi.org/10.1016/j.asams.2007.10.001
 
Coffey G., DeGuzman F., Inagaki M., Pak Y., Delaney S. M., Ives D., Betz A., Jia Z. J., Pandey A., Baker D., Hollenbach S. J., Phillips D. R., Sinha U. (2012): Specific Inhibition of Spleen Tyrosine Kinase Suppresses Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis. Journal of Pharmacology and Experimental Therapeutics, 340, 350-359 https://doi.org/10.1124/jpet.111.188441
 
Eklund Kari K, Joensuu Heikki (2009): Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Annals of Medicine, 35, 362-367 https://doi.org/10.1080/07853890310001339
 
Fisher M (2002): Disseminated granulomatous meningoencephalomyelitis in a dog. The Canadian Veterinary Journal 43, 49–51.
 
Granger Nicolas, Smith Peter M., Jeffery Nick D. (2010): Clinical findings and treatment of non-infectious meningoencephalomyelitis in dogs: A systematic review of 457 published cases from 1962 to 2008. The Veterinary Journal, 184, 290-297 https://doi.org/10.1016/j.tvjl.2009.03.031
 
Greer K. A., Wong A. K., Liu H., Famula T. R., Pedersen N. C., Ruhe A., Wallace M., Neff M. W. (2010): Necrotizing meningoencephalitis of Pug Dogs associates with dog leukocyte antigen class II and resembles acute variant forms of multiple sclerosis. Tissue Antigens, , - https://doi.org/10.1111/j.1399-0039.2010.01484.x
 
Inayat Mohammed S, El-Amouri Ismail S, Bani-Ahmad Mohammad, Elford Howard L, Gallicchio Vincent S, Oakley Oliver R (2010): Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox. Journal of Inflammation, 7, 43- https://doi.org/10.1186/1476-9255-7-43
 
JUNG Hae-Won, LEE Hee-Chun, KIM Ji-Hyun, JANG Hyo-Mi, MOON Jong-Hyun, SUR Jung-Hyang, HA Jeongim, JUNG Dong-In (2014): Imatinib Mesylate plus Hydroxyurea Chemotherapy for Cerebellar Meningioma in a Belgian Malinois Dog. Journal of Veterinary Medical Science, 76, 1545-1548 https://doi.org/10.1292/jvms.14-0001
 
Lori Franco (1999): Hydroxyurea and HIV: 5 years later-from antiviral to immune-modulating effects. AIDS, 13, 1433-1442 https://doi.org/10.1097/00002030-199908200-00001
 
MATSUKI Naoaki, FUJIWARA Kaori, TAMAHARA Satoshi, UCHIDA Kazuyuki, MATSUNAGA Satoru, NAKAYAMA Hiroyuki, DOI Kunio, OGAWA Hiroyuki, ONO Kenichiro (2004): Prevalence of Autoantibody in Cerebrospinal Fluids from Dogs with Various CNS Diseases. Journal of Veterinary Medical Science, 66, 295-297 https://doi.org/10.1292/jvms.66.295
 
Mirshafiey A, Ghalamfarsa G, Asghari B, Azizi G (2014): Receptor tyrosine kinase and tyrosine kinase inhibitors: New hope for success in multiple sclerosis therapy. Innovations in Clinical Neuroscience 11, 23–36.
 
Munana KR, Luttgen PJ (1998): Prognostic factors for dogs with granulomatous meningoencephalomyelitis: 42 cases (1982–1996). Journal of the American Veterinary Medical Association 212, 1902–1906.
 
O'Neill Emma J, Merrett Darren, Jones Boyd (2005): Granulomatous meningoencephalomyelitis in dogs: A review. Irish Veterinary Journal, 58, 86- https://doi.org/10.1186/2046-0481-58-2-86
 
Park E. S., Uchida K., Nakayama H. (2012): Comprehensive Immunohistochemical Studies on Canine Necrotizing Meningoencephalitis (NME), Necrotizing Leukoencephalitis (NLE), and Granulomatous Meningoencephalomyelitis (GME). Veterinary Pathology, 49, 682-692 https://doi.org/10.1177/0300985811429311
 
Reardon David A., Norden Andrew D., Desjardins Annick, Vredenburgh James J., Herndon James E., Coan April, Sampson John H., Gururangan Sridharan, Peters Katherine B., McLendon Roger E., Norfleet Julie A., Lipp Eric S., Drappatz Jan, Wen Patrick Y., Friedman Henry S. (2012): Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. Journal of Neuro-Oncology, 106, 409-415 https://doi.org/10.1007/s11060-011-0687-1
 
Shah Gaurav D., Silver Joel S., Rosenfeld Steven S., Gavrilovic Igor T., Abrey Lauren E., Lassman Andrew B. (2007): Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas. Journal of Neuro-Oncology, 85, 217-222 https://doi.org/10.1007/s11060-007-9408-1
 
Sospedra Mireia, Martin Roland (2016): Immunology of Multiple Sclerosis. Seminars in Neurology, 36, 115-127 https://doi.org/10.1055/s-0036-1579739
 
SUZUKI Mari, UCHIDA Kazuyuki, MOROZUMI Motoji, HASEGAWA Takashi, YANAI Tokuma, NAKAYAMA Hiroyuki, TATEYAMA Susumu (2003): A Comparative Pathological Study on Canine Necrotizing Meningoencephalitis and Granulomatous Meningoencephalomyelitis. Journal of Veterinary Medical Science, 65, 1233-1239 https://doi.org/10.1292/jvms.65.1233
 
Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV (2002): Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia, 16, 2349-2357 https://doi.org/10.1038/sj.leu.2402775
 
Vermersch Patrick, Benrabah Rabah, Schmidt Nicolas, Zéphir Hélène, Clavelou Pierre, Vongsouthi Cyrille, Dubreuil Patrice, Moussy Alain, Hermine Olivier (2012): Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurology, 12, - https://doi.org/10.1186/1471-2377-12-36
 
download PDF

© 2019 Czech Academy of Agricultural Sciences